Jasper Therapeutics Inc [NASDAQ: JSPR] plunged by -$0.14 during the normal trading session on Tuesday and reaching a high of $2.4199 during the day while it closed the day at $1.58.
Jasper Therapeutics Inc stock has also loss -8.14% of its value over the past 7 days. However, JSPR stock has declined by -41.91% in the 3 months of the year. Over the past six months meanwhile, it has lost -73.22% and lost -93.20% year-on date.
The market cap for JSPR stock reached $44.21 million, with 27.98 million shares outstanding and 24.26 million shares in the current float. Compared to the average trading volume of 418.81K shares, JSPR reached a trading volume of 58968005 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Jasper Therapeutics Inc [JSPR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JSPR shares is $12.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JSPR stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Jasper Therapeutics Inc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on July 08, 2025. The new note on the price target was released on July 08, 2025, representing the official price target for Jasper Therapeutics Inc stock.
The Price to Book ratio for the last quarter was 3.82, with the Price to Cash per share for the same quarter was set at 1.82.
JSPR stock trade performance evaluation
Jasper Therapeutics Inc [JSPR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.14. With this latest performance, JSPR shares dropped by -30.70% in over the last four-week period, additionally sinking by -73.22% over the last 6 months – not to mention a drop of -92.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JSPR stock in for the last two-week period is set at 34.72, with the RSI for the last a single of trading hit 0.2295, and the three-weeks RSI is set at 0.2006 for Jasper Therapeutics Inc [JSPR]. The present Moving Average for the last 50 days of trading for this stock 2.1441, while it was recorded at 1.7270 for the last single week of trading, and 3.7738 for the last 200 days.
Jasper Therapeutics Inc (JSPR) Capital Structure & Debt Analysis
According to recent financial data for Jasper Therapeutics Inc. ( JSPR), the Return on Equity (ROE) stands at -191.12%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -116.04%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Jasper Therapeutics Inc’s Return on Invested Capital (ROIC) is -786.63%, showcasing its effectiveness in deploying capital for earnings.
Jasper Therapeutics Inc (JSPR) Efficiency & Liquidity Metrics
Based on Jasper Therapeutics Inc’s (JSPR) latest financial statements, the Debt-to-Equity Ratio is 0.15%, indicating its reliance on debt financing relative to shareholder equity.
Jasper Therapeutics Inc (JSPR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Jasper Therapeutics Inc. (JSPR) effectively leverages its workforce, generating an average of -$1422187.5 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.59% and a Quick Ratio of 2.59%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Jasper Therapeutics Inc [JSPR] stock
With the latest financial reports released by the company, Jasper Therapeutics Inc posted -1.62/share EPS, while the average EPS was predicted by analysts to be reported at -1.23/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.39. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JSPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jasper Therapeutics Inc go to 23.19%.
Jasper Therapeutics Inc [JSPR]: Institutional Ownership
There are presently around $72.68%, or 73.45%% of JSPR stock, in the hands of institutional investors. The top three institutional holders of JSPR stocks are: VELAN CAPITAL INVESTMENT MANAGEMENT LP with ownership of 1.47 million shares, which is approximately 9.8216%. SOLEUS CAPITAL MANAGEMENT, L.P., holding 1.28 million shares of the stock with an approximate value of $$28.97 million in JSPR stocks shares; and SOLEUS CAPITAL MANAGEMENT, L.P., currently with $$24.2 million in JSPR stock with ownership which is approximately 7.1144%.
